Sunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rights

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months. The newly launched drug is Prucalopride, a generic version of Resotran, In the United States, Prucalopride is sold under the brand name, Motegrity. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility. Nora Pharma’s Prucalopride is available in blisters packs of 28 tablets for the Canadian market in strengths of 1 mg and 2 mg. Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market.